AzTrials
AzTrials

Attention Deficit Hyperactivity DisorderPhase 4NCT02545634

Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children

A Phase 4 study testing L. helveticus R0052 and B. longum R0175 in people with Attention Deficit Hyperactivity Disorder and Anxiety, run by Acadia University at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study will examine the effect of a probiotic supplement (Lactobacillus helveticus R0052 and Bifidobacterium Longum R0175) dissolved in a dairy product such as milk or ice-cream on symptoms of ADHD and anxiety in children. Read more about this study

Who is it for?
Ages 6 to 14 years
What is being tested?
L. helveticus R0052 and B. longum R0175
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteCanada
Study dates
Jun 2015to Jun 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 14 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • average score of 2.5 or higher on either the hyperactive/impulsive or inattentive symptoms on eligibility questionnaire
  • total score of 10 or higher on the anxiety eligibility questionnaire

Who cannot join

  • Dairy or Soy allergy
  • Currently taking antibiotics
  • HIV/AIDS
  • Diagnosis of Cancer, Crohn's Disease, or Ulcerative Colitis
  • Undergoing chemotherapy

Trial locations and contacts

1 site in 1 country.

Susan Potter, Phd. contact

902-585-1220

susan.potter@acadiau.ca

Patrick Bazinet, BAh contact

9027903548

bazinet.patrick@gmail.com

Canada1 site, 1 recruiting
  • Acadia University

    Wolfville, Nova Scotia, B4P 2R6

    Susan Potter, Phd., 902-585-1220, susan.potter@acadiau.ca

    Patrick Bazinet, BAh, 9027903548, bazinet.patrick@gmail.com

    Recruiting

Other trials in Canada

About this study

Official title: Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children

The study will examine the effect of a probiotic supplement (Lactobacillus helveticus R0052 and Bifidobacterium Longum R0175) dissolved in a dairy product such as milk or ice-cream on symptoms of ADHD and anxiety in children. The main goal is to determine if probiotics might be useful as a treatment for anxiety and ADHD symptoms in children. A second goal is to examine the effects of probiotics on saliva cortisol levels. Finally, the investigators are also interested in the effects of the probiotics on children's digestive health.

Read the detailed description

Participants will be recruited using information distributed through schools in the Annapolis Valley area and with the use of advertising campaigns visible across Nova Scotia as previously described. Interested participants will be directed to the study's website (www.probioticstudy.com), where they will be able to view a complete summary of the study's timeline and details. After reviewing the website, guardians of potential participants will be able to complete an initial consent form and preliminary questionnaire in order to determine their child's eligibility for participation. The process of completing the consent form and initial questionnaires is expected to take approximately 15 minutes. Participants' responses to the preliminary questionnaire will be reviewed by the researchers, and initial appointments will be scheduled, either at the Acadia University location or the Halifax location.

Each participant will be enrolled in the study for a thirteen-week period with a six-month follow-up session. The first week will be an information-gathering week during which participants will complete a daily food diary online with their parents' assistance. Each evening during this initial week, and at the end of each week throughout the study period, the child will answer a few questions about his or her symptoms of anxiety and/or ADHD, and gastrointestinal health. Parents/guardians will answer parallel questions about the child's symptoms of anxiety and/or ADHD.

Confidentiality will be maintained by assigning each participant a code number based on the last four digits of their phone number and the first letter of their last name when they begin the study (for siblings the first letter of their first name will be used). The food diary and all other subsequent questionnaires will be matched with the participant's data via their code number. Participants or their guardians will be required to remember their individual code, although, in the event they forget their code number, a master list will be kept on an external hard-drive in an encrypted, password-protected file, locked in the researchers' office.

During or shortly after the food-diary week, the researcher will schedule a meeting with each participant and guardian in order to provide detailed instructions on the first phase of the study and to obtain informed consent for continuation in the study from the parent/guardian and assent from the child. During the first meeting parents/guardians will complete study outcome measures. Child participants will also complete outcome measures and cognitive tests. These measures will be administered once again following the completion of the first phase (week five), following the four-week wash-out period (week nine), and the second phase (week thirteen). These measures are the clinical trial's primary end-points.

Following the information-gathering week, participants will begin the first phase of the study. They will consume either the probiotic or placebo powder taken with milk or ice cream for four weeks. For the second phase, the conditions will be reversed, and the participant will consume the alternate substance for four weeks; thus, all participants will receive the probiotic in one phase and the placebo in another phase. The order in which participants receive the probiotics and placebo will be randomized within groups of ten participants to ensure counterbalancing - i.e., roughly equal numbers of participants receiving probiotics and placebo in the first phase. The four-week intervention phases will be separated by a four-week washout period to ensure that any potential residual effects from the first phase have passed by the time the second phase commences. Following the wash-out period, participants will complete the relevant outcome measures once again to establish baseline scores prior to beginning the second intervention phase. Because this a double-blind design, the participants, their parents/guardians and the researchers administering the probiotics and placebos will not be aware which powder (probiotic or placebo) the participant is receiving in each of the two phases; only the Clinical Director at Lallemand Health Solutions will be privy to the experimental condition of the participants. Morning saliva samples for cortisol analysis will be collected from participants during weeks two (baseline visit), five (second visit), nine (third visit), and thirteen (fourth visit) of the study.

During the first week of each phase, the researcher will contact the participants by email or phone on the third and sixth day to check in and make sure participants/their guardians do not have any concerns and/or questions regarding their participation. Following the initial week of each phase, participants will be contacted weekly in order to monitor progress and address any concerns.

During first and second meetings, parents will be supplied with either probiotic or placebo powder as well as detailed instructions for the first and second intervention phases. At the fourth and final appointment, participants will complete the aforementioned questionnaires (if not done online) and be given the opportunity to ask any questions they may have about the study. If participants wish to know during which phase they received the probiotic formula, they be supplied with this information following the completion of the study.

Being tested
L. helveticus R0052 and B. longum R0175, Placebo
Keywords
probiotic, ADHD, anxiety, digestive health, children, attention deficit, gut brain axis, nutritional supplement, microbiome
Medical subject headings
Attention Deficit Disorder with Hyperactivity, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • L. helveticus R0052 and B. longum R0175Dietary supplement

    Also called Probiostick, Jamieson Probiotic Sticks, Health Canada Natural Product Number (NPN) 80021343

    See arm descriptions for intervention description.

  • PlaceboOther

Study groups in NCT02545634
Study groupRoleWhat they receive
Placebo powderPlacebo comparatorPlacebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
Receives: Other: Placebo
Probiotic powderExperimentalThe Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
Receives: Dietary Supplement: L. helveticus R0052 and B. longum R0175

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale

    Measured: First day of study participation and again at weeks 4, 8, and 12

Secondary outcomes (5)
  1. Change in Salivary cortisol

    Measured: First day of study participation and again at weeks 4, 8, and 12

  2. Change in total score on the Screen for Child Anxiety Related Emotional Disorders

    Measured: First day of study participation and again at weeks 4, 8, and 12

  3. Change in Word Pairs Memory Test

    Measured: First day of study participation and again at weeks 4, 8, and 12

  4. Change in Visual Memory Test

    Measured: First day of study participation and again at weeks 4, 8, and 12

  5. Change in total omission and commission errors on the Continuous Performance Task

    Measured: First day of study participation and again at weeks 4, 8, and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2015 (estimated)
  2. Study startJun 2015
  3. Primary completionMay 2016 (estimated)
  4. Study completionJun 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02545634
Sponsor's protocol ID
APB-C1
Status last verified
Sep 2015
First submitted
30 Jul 2015
Last updated
10 Sep 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing L. helveticus R0052 and B. longum R0175 in people with Attention Deficit Hyperactivity Disorder and Anxiety, run by Acadia University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Susan Potter, Phd. (902-585-1220, susan.potter@acadiau.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale (time frame: First day of study participation and again at weeks 4, 8, and 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in